Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Return on Sales (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Return on Sales for 15 consecutive years, with 3.17% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 65.0% to 3.17% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.65%, a 13.0% decrease, with the full-year FY2024 number at 2.51%, up 20.0% from a year prior.
  • Return on Sales was 3.17% for Q3 2025 at Plus Therapeutics, down from 1.09% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 30.56% in Q2 2022 to a low of 71.49% in Q3 2022.
  • A 5-year average of 3.46% and a median of 2.6% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: plummeted -8996bps in 2022, then soared 6881bps in 2023.
  • Plus Therapeutics' Return on Sales stood at 18.47% in 2021, then plummeted by -341bps to 44.46% in 2022, then soared by 93bps to 2.93% in 2023, then grew by 6bps to 2.76% in 2024, then fell by -15bps to 3.17% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Return on Sales are 3.17% (Q3 2025), 1.09% (Q2 2025), and 3.86% (Q1 2025).